Jinhe Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.02%

Jinhe Biotechnology Co Ltd (002688) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jinhe Biotechnology Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥1.37 Million
≈ $200.01K USD Cash + Short-term Investments

Total Assets

CN¥5.58 Billion
≈ $817.26 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Jinhe Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jinhe Biotechnology Co Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Jinhe Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Jinhe Biotechnology Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.37 Million 0.02%
Total Liquid Assets CN¥1.37 Million 0.02%

Asset Resilience Insights

  • Limited Liquidity: Jinhe Biotechnology Co Ltd maintains only 0.02% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jinhe Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jinhe Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Jinhe Biotechnology Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Jinhe Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.01% CN¥553.12K
≈ $80.94K
CN¥5.65 Billion
≈ $826.86 Million
+0.00pp
2023-12-31 0.01% CN¥507.66K
≈ $74.29K
CN¥5.45 Billion
≈ $798.06 Million
+0.16pp
2021-12-31 -0.15% CN¥-6.24 Million
≈ $-912.65K
CN¥4.06 Billion
≈ $594.77 Million
+0.26pp
2020-12-31 -0.41% CN¥-13.97 Million
≈ $-2.04 Million
CN¥3.38 Billion
≈ $494.14 Million
-0.10pp
2019-12-31 -0.31% CN¥-10.34 Million
≈ $-1.51 Million
CN¥3.34 Billion
≈ $489.37 Million
-0.37pp
2018-12-31 0.06% CN¥2.14 Million
≈ $313.21K
CN¥3.34 Billion
≈ $488.07 Million
+0.26pp
2016-12-31 -0.20% CN¥-5.23 Million
≈ $-766.04K
CN¥2.66 Billion
≈ $389.58 Million
--
pp = percentage points

About Jinhe Biotechnology Co Ltd

SHE:002688 China Drug Manufacturers - Specialty & Generic
Market Cap
$580.38 Million
CN¥3.97 Billion CNY
Market Cap Rank
#11575 Global
#3290 in China
Share Price
CN¥5.14
Change (1 day)
-0.58%
52-Week Range
CN¥4.62 - CN¥7.11
All Time High
CN¥10.94
About

Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.